Skip to content

Coronavirus (COVID-19)

We have a number of temporary service changes in light of the Coronavirus pandemic. Temporary changes to our services.


We have a range of information and advice here: Coronavirus information.

Suffering anxiety, depression, low mood, stress?

We can help! Free, confidential NHS talking therapy service to help you. For more details visit Improving Access to Psychological Therapies.

Current research studies

For information about any of our research please email:

Covid-19 Research

Psychological Impact of Coronavirus – pandemic and experience: An international survey

The aim of this survey is to better understand how the coronavirus pandemic and resultant restrictions/lockdown are affecting our day-to-day lifestyle. We hope to find out what is helpful for people during this time and what may be causing some people to be affected more than others in terms of their wellbeing. Anyone over the age of 16 can take part.

If you do complete the survey, please ensure that you select the Rotherham Doncaster and South Humber (RDaSH) NHS Foundation Trust from the drop-down list when answering where you heard about the study.’

Phase 1 of the study took place April 2020 to July 2020 and a paper has been published on the data gathered during the first three weeks. To access the report please click here.

Want to find out more? Just click on this link:

Closes 21/09/2021


CO-CAT: Child Anxiety Treatment in the contact of Covid-19

The study is to compare a parent-led treatment which involves access to content on a website and with therapist support throughout for anxiety difficulties in children with the usual treatment that is currently being offered to treat child anxiety difficulties. The study is taking place across England, including in the clinical service that will be delivering your child’s treatment.

If your child is eligible, you will be told when they are referred into the service.

Closes 31/10/2021



Platform Randomised trial of INterventions against COVID-19 in older peoPLE

This is a nationwide clinical trial from the University of Oxford to find COVID-19 treatments for the over 50s that can be taken at home.

The study is looking for medicines that can help people with COVID-19 symptoms get better quickly and stop them needing to go to hospital.

The trial is recruiting participants through its website and through GP practices across the UK.


UpLift Trial

Occupational burnout is known to affect many NHS staff, adversely impacting their job satisfaction, job performance, relationships at work, general health and wellbeing. The COVID-19 pandemic has led to a major increase in stressful conditions and pressures that exacerbate occupational burnout. This trial will provide NHS workers with easy access to interventions designed to reduce occupational burnout and improve their wellbeing.

NHS workers will participate in six video-based group workshops delivered via Microsoft Teams, and they will have access to a dedicated App which includes online resources such as videos, worksheets, and self-help tools. There are two interventions developed by our team to improve NHS staff wellbeing and reduce occupational burnout. One intervention has a well-established evidence base; the second intervention is novel and has no prior empirical support, but it is well informed by the latest science and evidence bases in the fields of psychology and occupational health. Both interventions will be delivered online, as described above. Participants will be randomly allocated to one of these interventions, so that we can compare their effectiveness.

Closed to recruitment: 02/07/2021


ISARIC/WHO Clinical Characterisation Protocol (CCP)

Infectious diseases affect millions of people around the world every year. Most cases are mild, but some people become very unwell. There is a great deal that we do not understand about existing infections, and new infectious diseases continue to appear. This research study will gain important information about respiratory infections so we can try to find better ways to manage and treat them in the future.

Some trial sites will collect blood, sputum and urine samples as well as medical data from patients hospitalised with Covid-19.

RDaSH is what is called a tier 0 site, which means we are only collecting completely anonymous data from medical records, no patient identifiable data will be collected.

For information about any of our research please email:


Other Research

 Social Environment and Early Psychosis: An Urban Mind Study

The study is designed to help us understand how social environment and stress affect mental wellbeing in the early stages of psychosis.  While most research on the social environment in people with psychosis has focused on specific features of the social environment, individual or environmental characteristics are rarely considered.  This trial will examine how individuals respond to the social environment by using a smartphone app called Urban Mind. Urban Mind is an app that will measure experience of the social environment in the real time. The app uses Ecological Momentary Assessment (EMA) – a technique that involves multiple tests of how someone feels and what they do as they go about their daily life.

By collecting real-time data (information), we will be able to understand how ‘social stress sensitivity’ and ‘social withdrawal’ affect mental wellbeing and future mental health. The results of this study will be used to design and create a new smartphone app to predict the chance of relapse in patients with psychosis.

Closes 30/09/2023


Hearing Nasty Voices: Developing new ways to measure the experience

This is part of a series of studies which are aiming to discover why negative and threatening voices (nasty voices) can be so believable and difficult to ignore.  By doing this, we hope that we can develop better psychological support for people who hear nasty voices.  One important area of this work is developing new ways to measure the experience of hearing nasty voices.  This study aims to develop two specific questionnaires. To do this, we need to test which questions are the best questions to ask.  This is what this study is designed to find out.

Closes 29/10/2021


Understanding Feelings of Being Exceptional

This study aims to find out more about peoples’ experience of feeling exceptional, special, or extraordinary. This could include special abilities, identity, power, or knowledge. People with these experiences have told us that they can be positive but can also be distressing for some people. They are not currently well understood by researchers or clinicians. We are therefore trying to understand more about what these experiences are like, what keeps them going, and the impact that they have on people. We also want to develop some new questionnaires, which would help us to understand these experiences better. This is so that in the future we can develop better support for people with these experiences who might find this helpful.

People do not need to have any experiences of feeling exceptional to participate in the study. All experiences are equally helpful to our research. Having people in the study who have experiences of feeling exceptional and people who do not have these experiences, can help us to understand better why some people might have these experiences while others do not.

Closes 03/3/2022


Outcomes of Aggression

Learning disability begins in childhood, and is defined by limited cognitive ability and significant problems in adaptive functioning (e.g. relationships and independent living). Aggression is a common problem in adults with learning disabilities. Consequences of aggression include reduced quality of life, risks to the physical safety of the individual or others, excessive use of restrictive practices and significant economic costs. There are current gaps in research on the prognosis of aggression, associations with mental and physical health and response to treatment. Parents of adults with learning disability report a lack of a preventive and holistic approach to managing aggression, with a wish to see more psychosocial interventions, continuity of care, early intervention, and preventive strategies.

This is a study to develop a new personalised treatment package for adults with learning disabilities who display aggression. To do this, we would like to explore the views of health and social care professionals about the interventions or treatments the person with learning disability whom they work with, has had for managing their aggression. We want to find out what has worked well and what has not worked well and the factors that may have influenced why someone has responded well or poorly to a particular treatment. We will also be inviting the person with learning disability and their carer, to also take part in the study.

Recruitment of patients and carers has now closed but we are still looking for healthcare professionals.

Closes 30/7/2021


ALLHEAL and Liver

This research study is creating a database of people who drink too much alcohol, either now or in the past. The purpose of this study is to help us understand the medical effects of dangerous drinking so that we can offer better advice and help to people.

Participants will be asked for some baseline data about their drinking and to consent for their medical record to be accessed and data to be recorded in a research database (for example medical problems and any medications).

RDaSH is a data collection centre for the research database which is maintained by researchers at Leeds Teaching Hospitals.

Closes 01/3/2022


Sleep Impulsivity Behaviour (SIB)

This research project, led by Dr Caroline Richards, is based in the School of Psychology at the University of Birmingham. The project aims to better understand behaviour in children with autism and intellectual disability. In the future, the information obtained during this study could help us to identify ways in which we may be able to prevent the onset of particular behaviours that have a negative impact on the quality of life of children with autism and intellectual disability.

This study is looking to recruit the parents/carers of children aged between 4 years and 15 years 9 months old who have autism and intellectual disability.

Closes 30/09/2022


STADIA: Standardised Diagnostic Assessment for Children and Young People

Lots of children and young people experience emotional difficulties, such as feeling sad or anxious, or having worries. Sometimes these difficulties can be very upsetting, and have an impact on day-to-day life, school, friendships and relationships. If a health professional, teacher or the family think that these difficulties might need specialist help the child/young person may be referred to CAMHS.

When a young person is referred to CAMHS, the service will review the information they have received and decide the most appropriate way to support the family. Sometimes referrals to CAMHS are not accepted but parents/carers may be advised to seek help elsewhere. Sometimes it can take a long time before children get the help they need.

We want to find out whether collecting extra information when people are referred to CAMHS helps with understanding their difficulties and offering the right help.

Closes 31/02/2022.



In the context of COVID-19, NHS Child, and Adolescent Mental Health Services (CAMHS) face major challenges in providing psychological treatments that (i) work when delivered remotely, and (ii) can be delivered efficiently to manage an anticipated increase in referrals as social distancing measures are relaxed. Anxiety problems are a common reason for referral to CAMHS, children with pre-existing anxiety problems are particularly vulnerable in the context of COVID-19, and there are concerns about likely increases in childhood anxiety as schools reopen. We worked with children, parents and NHS clinicians to develop an online program (the OSI platform) that parents/carers of children with anxiety disorders work through with remote support from a CAMHS therapist. We will now test whether the OSI platform together with therapist support works as well as what CAMHS are currently offering to help children with anxiety problems (while social distancing measures are in place and in the post COVID-19 recovery phase), and whether OSI as delivered with therapist support brings wider benefits to families and CAMHS. We will also provide an understanding of parents’ and therapists’ experiences of digital treatments in CAMHS in the context of COVID-19. This research has the potential to create a step change in the digital delivery of treatments in CAMHS, bringing benefits in the COVID-19 context and beyond.

Closes 31/10/2021


PolyX: Polygene algorithm for weight gain in first episode psychosis

The purpose of the study is to determine whether a polygene-based algorithm will enable the identification of individuals at greatest risk of weight gain in the early stages of psychosis. The study will combine existing data collected as part of routine clinical care, including weight change, medication dose and duration of treatment with a DNA sample collected by mouth swab. If we successfully determine the value of a polygene-based algorithm in this context, consideration can be given to the use of weight neutral pharmacotherapy and lifestyle modulating strategies in this group.

Closes 01/01/2022


Home Goals: A randomised controlled trial to improve mental and physical health and well-being in young people

The project aims to create therapy groups for children to improve their mental and emotional wellbeing. Each therapy group runs for one hour after school for six weeks, one half an hour focussing on physical activity (led by a local sports club) and another half an hour focusing on psychoeducation, led by NHS staff (e.g mental health nurse, psychiatrist, psychologist, Psychological Well-being Practitioners). The physical health aspect of the groups encompasses a broad range of physical activities, adapted to try at home. The groups also enable young people to learn about how and why anxiety and depression occur, and how we can learn ways of managing them. This project is especially crucial given the nature of the COVID-19 pandemic, and ensuring the safety of staff and patients, by allowing the delivery of the interventions over video-conferencing software.

Closes 01/08/2021


Food Rewards

The main medications used to treat schizophrenia/other psychotic illnesses cause significant weight gain, as identified in established product literature for antipsychotic agents b) established research available c) current NICE guidelines. Consequent obesity can also lead to failure to take medication, reduced psychological well-being and stigma. Weight gain is one of the most powerful predictors for the future development of type 2 diabetes, cardiovascular disease and metabolic syndrome with short term weight gain predicting longer term weight gain. Anecdotal evidence suggests that patients treated with olanzapine, quetiapine and other atypical antipsychotic agents experience increased food craving and reduced satiation. This is supported by limited longitudinal data. We propose a pilot study to be conducted in Greater Manchester that will gather important information in relation to the psychological and hormonal/metabolic drivers of weight change. This will afford us not only an estimation of changes in eating behaviour/attitude, but also craving and fat/ sugar consumption and food and nutrient intakes. Our aim is that with these measures we can achieve greater understanding of the specific mechanisms that might be meditating the changes in food responsiveness.

Closes 02/03/2022


Psychosocial interventions in intensive home treatment

The aim of this research is to conduct a pre-protocol consultation with people who have a range of different expertise and experiences of intensive home treatment in adult mental health services. The protocol under developments would seek to develop a therapeutic model of psychosocial interventions for intensive home treatment in mental health. This study will use focus groups to explore their experiences of the service and the focus, scope and design of a proposed mixed method realist evaluation research study. Data will be collected from four focus groups held in two NHS organisations that provide intensive home treatment interventions, two groups will be held with service users and carers and two groups held with staff. Participant experience of taking part in the focus groups will be evaluated using a graffiti wall and brief questionnaire and reported using the GRIPP2 guidelines. Data will be analysed using and inductive qualitative thematic analysis supported by Nvivo. Findings will be reported in peer-reviewed academic journals, meetings and conferences and used to support the development of an NIHR researcher-led proposal.

Closes 31/01/2022

For information about any of our research please email:


RDaSH led research delivered by GP Practices

Clinical pharmacist eczema in children study

Patient education plays a key role in the successful management of atopic eczema. While Government policy supports the role of pharmacists in those with long-term conditions such as atopic eczema, there is not enough evidence yet to confirm that educational interventions by pharmacists can reduce the severity of eczema.

This study will investigate the impact on disease severity following an educational intervention provided by general medical practice-based, clinical pharmacists to parents/carers of children with atopic eczema. Parents of children aged between six months and six years of age will be invited to a consultation with the clinical practice-based pharmacist. During the consultation, pharmacists will assess parent/carer’s knowledge and understanding of Atopic Eczema and ask participants to complete a specific eczema disease severity tool. At a follow-up appointment, the pharmacists will re-check participant knowledge and understanding of eczema and repeat the eczema severity tool to assess for any changes.

The study has the potential to demonstrate the valuable contribution to care of patients with atopic eczema by practice-based pharmacists. If successful, the results would serve as an exemplar of best practice that can be more widely adopted within the NHS.

For more information, please see below:

ECZEMA STUDY – participant information sheet

Closing date: 31/12/2021


The use of a screening tool in primary care to identify menopausal and perimenopausal women who could benefit from Hormone replacement therapy

The menopause represents a normal physiological change that occurs on average occurs in women age 50. Though not strictly an illness, the low levels of oestrogen associated with the menopause commonly results in symptoms such as hot flushes, night sweats and many other symptoms. Hormone replacement therapy (HRT) is an effective treatment for menopausal symptoms but media reports of an increased risk of cancers have led to a decrease in the number of women using HRT even though symptoms can have a large and negative effect on quality of life.

Participants in the study will complete an assessment of the impact of menopause on quality of life by completing two questionnaires and taking part in an educational consultation with their practice pharmacist.

The study has the potential to involve clinical practice-based pharmacists in the management of women with menopausal symptoms and to ensure that they can make an informed choice on the use of HRT and are managed in accordance with the NICE guideline.

For more information, please se below:

HRT STUDY participant information sheet

Closing date: 31/12/2021

For information about any of our research please email: